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Extracellular vesicles (EVs) are biological nanoparticles with important roles in intercellular
communication, and potential as drug delivery vehicles. Here we demonstrate a role for the
glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in EV assembly and
secretion. We observe high levels of GAPDH binding to the outer surface of EVs via a
phosphatidylserine binding motif (G58), which promotes extensive EV clustering. Further
studies in a Drosophila EV biogenesis model reveal that GAPDH is required for the normal
generation of intraluminal vesicles in endosomal compartments, and promotes vesicle
clustering. Fusion of the GAPDH-derived G58 peptide to dsRNA-binding motifs enables
highly efficient loading of small interfering RNA (siRNA) onto the EV surface. Such vesicles
efficiently deliver siRNA to multiple anatomical regions of the brain in a Huntington’s disease
mouse model after systemic injection, resulting in silencing of the huntingtin gene in different
regions of the brain.
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Extracellular vesicles (EVs) are emerging as important med-iators of intercellular communication by which cells canexchange information in the form of lipids, proteins or
nucleic acids1. EVs are lipid bilayer-enclosed nanoscale particles
that contain membrane-associated proteins and cytosolic com-
ponents derived from the parent cell2. There are several classes of
EVs, but small EVs with a diameter of 30–150 nm are the most
well-studied3. They are secreted by cells as exosomes formed in
intracellular endosomal compartments or as microvesicles shed
from the cell surface. Given their unique biological and phar-
macological characteristics, EVs have attracted interest as med-
iators of physiological and pathophysiological processes, and have
potential as cell-free therapeutics4. EVs have been reported to
play important roles in the regulation of the immune response5,
metastasis of cancer cells6,7, propagation of pathogenic proteins
involved in neurodegenerative disorders8, and are emerging as a
source of biomarkers for a variety of diseases9.
Although heterogeneity of EVs has complicated their mole-
cular characterization, significant advances have been made in
our understanding of their biogenesis in recent years10. Multiple
mechanisms of exosome and microvesicle biogenesis have been
identified that involve endosomal sorting complexes required for
transport (ESCRT)-dependent and ESCRT-independent pro-
cesses. Multiple cellular components have been identified that
participate in these processes including Alix, tumour suscept-
ibility gene 101 protein (TSG101), syndecan-syntenin complexes,
the tetraspanin family and lipid rafts11,12. However, we still lack a
detailed understanding of the regulatory and loading processes
involved.
EVs have also attracted considerable interest as potential
vehicles for drug delivery, particularly as carriers of macro-
molecules like non-coding RNAs and proteins13. Their immu-
nological inertness and ability to cross biological barriers are two
important features that can be exploited for therapeutic
applications14. EVs have been demonstrated to deliver ther-
apeutic small interfering RNAs (siRNAs) and antisense oligonu-
cleotides in multiple therapeutic contexts, including mouse
models resulting in suppression of pancreatic cancer and
restoration of dystrophin expression for the treatment of mus-
cular dystrophy, respectively15–17. However, an incomplete
understanding of EV biogenesis and uptake mechanisms, and a
lack of efficient drug loading methods remain critical challenges
that need to be addressed18,19. Current methods of loading
therapeutic molecules into EVs such as electroporation, genetic
engineering of host cells and chemical conjugation, are limited by
low efficiency, toxicity and lack of scalability20,21. Moreover, they
produce a heterogeneous population of EVs that generates further
complexity in terms of understanding the phenotypic effects of
EVs in target cells22. Development of methodologies in which the
natural properties of EVs are exploited for therapeutic applica-
tions is likely to provide a more robust approach to this problem.
During the last two decades, studies of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), traditionally known as a
‘housekeeping’ protein, have revealed multiple functions in cel-
lular processes that are independent of its canonical role in gly-
colysis. Earlier studies demonstrated that GAPDH is a nucleic
acid binding protein that prevents rapid shortening of telomeric
DNA, is involved in transport of tRNA and mRNA, regulates
expression of genes via specific binding to the 5′UTR and 3′UTR
of mRNA and possesses uracil DNA glycosylase activity involved
in repairing damaged DNA23–25. GAPDH is also a critical
mediator of cellular responses to oxidative stress. Under low
oxidative stress, GOSPEL (GAPDH’s competitor of Siah protein
enhances life) preserves glycolytic function of GAPDH and pre-
vents its S-nitrosylation. High oxidative stress levels induce
S-nitrosylation of GAPDH, leading to its interaction with Siah
and subsequent nuclear translocation, resulting in ubiquitylation
and degradation of nuclear proteins, triggering apoptosis26,27.
Recent reports have revealed complex and paradoxical roles for
GAPDH in preventing caspase-independent cell death (CICD) in
cancer cells. Overexpression of GAPDH stabilizes active Akt,
which in turn leads to overexpression of anti-apoptotic Bcl-xL,
which protects mitochondria permeabilization28. GAPDH also
participates in upregulation of autophagy protein ATG12, which
enhances autophagy and enables clearance of damaged mito-
chondria, preventing CICD, which in turn leads to clonogenic
outgrowth of cells29. Besides, its diverse physiological roles,
GAPDH is also involved in several neurological diseases. GAPDH
has been identified as a major component of amyloid plaques in
Alzheimer’s disease and is known to interact with amyloid −β
protein precursors30. The expanded polyglutamine repeats of
mutant huntingtin protein have been shown to associate with
GAPDH, potentially disrupting GAPDH-mediated trafficking of
damaged mitochondria into the lysosomal system31.
The functional diversity of GAPDH is attributed to its oligo-
meric nature, post-translational modifications and compartmen-
talization, allowing it to interact with different proteins32.
GAPDH is one of the most abundant proteins associated with
EVs, and has been reported to bind to the EV outer membrane,
where it interacts with the iron-binding proteins transferrin and
lactoferrin and traffics them into cells from tissue culture
medium33. Recently, it has been observed that GAPDH becomes
associated with exosomes during formation of intraluminal
vesicles and that exocytosis of exosomes represents one pathway
for secretion of GAPDH from cells, a process that is enhanced
when cells are depleted of iron34.
Here, we show that GAPDH associates with EVs via a
phosphatidylserine-binding motif, and that the addition of exo-
genous GAPDH to EV preparations induces EV clustering.
Analysis in an in vivo Drosophila model of exosome biogenesis in
the recycling endosomal compartments reveals that endogenous
GAPDH is involved in exosome clustering and the formation of
central dense granules in multi-vesicular endosomes, and also
affects exosome formation and secretion. Furthermore, chimeric
EV-binding G58 proteins that lack clustering activity, but are
fused with an RNA-binding domain, were shown to facilitate the
siRNA loading onto the EV surface and exhibit enhanced gene
silencing activity in cell culture, and in a mouse model of Hun-
tington’s disease.
Results
GAPDH binds cleaved lactoferrin N at the EV surface. In a set
of experiments designed to express the N-terminal region of
lactoferrin (hereafter lactoferrin N) on the surface of EVs for the
purposes of brain targeting35, we observed that lactoferrin N,
which was attached to the EV surface via fusion to DC-LAMP
(Dendritic cell lysosomal associated membrane glycoprotein), was
specifically cleaved from this anchor. Surprisingly, cleaved lac-
toferrin N (which lacks signal peptide and membrane-associated
domain) remained associated with the EV surface (Fig. 1a, b).
Previously, it was demonstrated that cells take-up extracellular
iron by secreting EVs carrying surface GAPDH, which interacts
with the iron-binding proteins lactoferrin and transferrin33.
Informed by these findings, we sought to determine whether
GAPDH is involved in anchoring lactoferrin to the EV mem-
brane. Using a protease digestion assay, we observed the presence
of GAPDH on the outer surface of EVs isolated from HEK293T,
HeLa, MSCs, SKOV-3 and B16 lymphoma cells (Supplementary
Fig. 1a & b). EV-associated GAPDH was found to be enzymati-
cally active (Supplementary Fig. 1c). Co-immunoprecipitation
experiments of HEK293T cell lysates and EVs demonstrated that
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the lactoferrin N domain is physically associated with GAPDH in
cells and on the surface of EVs (Supplementary Fig. 1d). Fur-
thermore, incubation of isolated EVs with purified lactoferrin N
protein resulted in efficient binding of the protein to the EV
surface. However, incubating purified EVs with a different
domain of lactoferrin, the N1.1 domain, which lacks the GAPDH
binding motif, did not result in binding to the EV surface (Sup-
plementary Fig. 1e & 2a). Taken together, these experiments
demonstrate the normal role of GAPDH in tethering lactoferrin
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Fig. 1 Surface binding of GAPDH leads to aggregation of EVs. a Cartoon representation of lactoferrin N cleavage from DC-LAMP by MMP-2 enzyme, and
attachment of the cleaved lactoferrin on the EV surface via GAPDH protein. b Western blotting of purified HEK293T EVs and cell lysate showing
expression of lactoferrin N-DC-LAMP and cleavage of lactoferrin from DC-LAMP (Dendritic cell-Lysosomal associated membrane protein). Arrangement
of the different domains of the protein is shown in the schematic. The experiment was independently repeated two times. c UV-absorbance spectrum for
EVs, EVs+GAPDH and EVs+BSA after passing through gel-filtration column. GAPDH and BSA protein alone were used as negative controls to rule out
aggregation of the proteins. The experiment has been independently repeated three times. d Western blot showing exogenous binding of GAPDH to
HEK293T EVs. Increasing concentrations of histidine-(His6) and Flag-tagged GAPDH were incubated with a fixed number of EVs. Endo GAPDH
Endogenous GAPDH, Exo GAPDH exogenous GAPDH. Alix and CD81 are EV protein markers used as positive controls. Calnexin (bottom blot) was used to
demonstrate the purity of EV samples. The experiment has been independently repeated two times. e GAPDH activity assay of EVs and EVs+Exo GAPDH.
For EVs+Exo GAPDH activity, GAPDH protein was added to EVs in concentrated (10×) complete tissue culture media (Media+ 10% FBS) followed by gel
filtration to isolate EVs. Results are shown as mean ± s.d (n= 3 independent biological experiments). f NTA profile showing the size distribution of purified
HEK293T EVs after incubation with either GAPDH or BSA proteins respectively. Inset is the scatter plot representing size (mean) of EVs. Data shown as
mean ± s.d. (n= 3 independent biological experiments) Statistical differences were determined by unpaired two-sided Student’s t-test. ***P < 0.0001. g
Electron microscopy images of EVs incubated with either BSA or GAPDH protein (scale bar indicates 200 nm). h Photographic images of tubes showing
the formation of thread-like structures from MSCs and HeLa EVs after incubation with GAPDH for 2 h at 4 °C. Experiment of (g and h) were independently
repeated two times. Source data are provided as a Source Data file.
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Binding of GAPDH to EVs causes EV clustering. We next
investigated whether additional GAPDH molecules could be
loaded onto EVs. Although overexpression of GAPDH in
secreting cells had a minimal effect on GAPDH loading, incu-
bation of isolated EVs with purified GAPDH resulted in extensive
surface binding of GAPDH, as confirmed by immunoblotting, gel
filtration and GAPDH enzymatic activity (Fig. 1c–e). The lack of
an ‘EV’ peak after loading GAPDH protein alone confirmed the
absence of any GAPDH aggregates in the sample (Fig. 1c).
Binding of GAPDH to EVs occurred for all cell sources tested,
and the presence of serum proteins in the tissue culture media did
not affect binding of GAPDH to EVs (Fig. 1e & Supplementary
Fig. 2b). Interestingly, incubation of EVs with GAPDH resulted in
an increase in EV particle size, as determined by nanoparticle
tracking analysis (Fig. 1f). Electron microscopy of HEK293T EVs
after incubation with GAPDH revealed the formation of long
branched chains of EVs (Fig. 1g). EVs derived from HeLa, B16-
F10 and mesenchymal stromal cells (MSCs) formed pronounced
thread-like structures when incubated with GAPDH protein,
suggesting that GAPDH induces EV clustering (Fig. 1h & Sup-
plementary Fig. 2d, e). An electron dense corona of GAPDH was
observed, tethering the EVs (Supplementary Fig. 2d). The width
of this tether was found to be around 13.54 ± 5.5 nm (mean ± s.d,
n= 30). Interestingly, it has recently been observed that newly
formed intraluminal vesicles (ILVs) from the limiting membrane
of some multi-vesicular bodies (MVBs), the compartments that
produce exosomes, are physically attached to each other via
electron dense tethers with an approximate width of ~12 nm36.
However, the biochemical nature of this tether remains to be
determined, although it is tempting to speculate that GAPDH is
involved.
GAPDH binds to EVs via a phosphatidylserine-binding G58
domain. GAPDH isolated from rabbit brain tissues has been shown
to induce fusion of synthetic lipid vesicles that contained phos-
phatidylserine (PS), cholesterol and plasmenylethanolamine37.
Interestingly, the fusogenic activity of GAPDH has also been
reported to play an important role in nuclear membrane
formation38. GAPDH protein has been reported to bind to the
nuclear membrane via a conserved PS-binding domain, located
between amino acids 70–94 (Supplementary Fig. 2c)39. Since PS is
present on the outer surface of EVs40, we next investigated whether
the G58 peptide is also responsible for binding of GAPDH to EVs.
To this end, we generated a fusion construct consisting of the PS-
binding motif of GAPDH (designated as G58) and the double-
stranded RNA-binding domain (dsRBD) of TARBP2 (TAR RNA-
binding protein 2), which could be detected with an anti-dsRBD
antibody. This chimeric protein (designated as G58T) was expres-
sed in, and purified from, E.coli cells. Purified G58T protein was
incubated with EVs for 2 h at 4 °C, and unbound protein was
separated from EVs by gel-filtration chromatography. Western
blotting and gel-binding assays revealed extensive binding of G58
peptide to the EV surface (Fig. 2a). However, binding of G58 did
not significantly alter the size of EVs (Fig. 2b), suggesting that
sequences outside of the GAPDH G58 motif, which are presumably
required for tetramerization, are involved in EV clustering. More-
over, Incubation of EVs with recombinant dsRBD of TARBP2 did
not result in EV binding, suggestive of specific binding of G58
peptide to the EV surface (Fig. 2c) Quantification of G58 binding
on MSC- and HEK293T-derived EVs revealed ~1200 and 1400 G58
peptide binding sites per EV, respectively (Supplementary Fig. 2f, g).
To determine whether other domains of GAPDH are involved
in mediating binding and clustering of EVs, we generated
different GAPDH mutants (Supplementary Fig. 3a). In the G150T
mutant, the NAD+ binding domain (1–150 amino acid) of
GAPDH that contains the PS-binding motif was fused to second
domain of TRBP2 protein and the recombinant DNA clone was
expressed in E. coli cells (Supplementary Fig. 3b). Incubation of
purified G150T protein with EVs resulted in efficient binding of
the protein to the surfaces of EVs, confirming that the catalytic
domain of GAPDH protein is not required for binding to EVs
(Supplementary Fig. 3c, d). In the GΔ(71–90) mutant, we deleted
the PS-binding domain of GAPDH but for unknown reasons we
could not express the protein in cells. To further characterize
binding of GAPDH to the EV surface, we mutated two important
amino acid residues of GAPDH (R80/A80 and K84/A84) within
the PS-binding domain that have been suggested earlier to have a
possible role in binding to PS lipids41. Substitution of R80 and
K84 to alanine did not affect expression levels of the mtGAPDH
protein produced, and it had similar glycolytic activity to
wtGAPDH (Supplementary Fig. 3e–g). However, we found a
significant decrease in EV binding of mtGAPDH when compared
to wtGAPDH (Supplementary Fig. 3h–k). Altogether, these
results confirm the presence of a specific PS-binding domain
within the NAD+ binding domain. Importantly, the ability of
specific amino acid changes to alter binding of GAPDH to the EV
surface without affecting glycolytic activity of the enzyme suggests
that the PS-binding domain is not required to mediate binding to
NADH or glyceraldehyde-3-phosphate, or for the catalytic
activity of the enzyme.
To assess whether GAPDH and G58 proteins bind to EVs
expressing canonical markers such as CD63, we next analyzed
EVs derived from HEK293F cells and MSCs by single vesicle
high-resolution Imaging Flow Cytometry (IFC). This method was
previously optimized extensively for detection and quantification
of single fluorescently labelled EVs with an Amnis Image
StreamX MkII instrument42. By staining CD63-neon GFP-tagged
EVs with APC-labelled anti-CD63 antibodies, we confirmed that
the Amnis Cellstream facilitates detection of single fluorescent
EVs (Fig. 2d). Endogenous GAPDH was detected on both
HEK293F cell and MSC-derived EVs (Fig. 2e). Incubation of EVs
from both cell lines with anti-GAPDH antibodies and fluores-
cently labelled G58 peptide resulted in detection of co-labelled
EVs (Fig. 2f), thereby confirming on the single EV level that
GAPDH is present on EVs derived from both cell lines and that
G58 binds extensively to those EVs.
To determine whether GAPDH secretion by cells is mediated
via EVs or if a non-vesicular route of GAPDH secretion also
exists, we expressed a GAPDH-GFP fusion protein in
HEK293T cells and isolated EVs from the cell cultured media.
Analysis of GAPDH-GFP fluorescence from EVs and non-EV
protein fractions reflected predominant association of GAPDH-
GFP in the non-EV protein fractions, suggesting the existence of
non-vesicular routes of GAPDH secretion, consistent with reports
from others (Fig. 2g)34,43.
GAPDH regulates exosome clustering, biogenesis and secre-
tion in vivo. A previous study has suggested that GAPDH is
preferentially loaded on to exosomes when cells are starved of
iron34. We have recently shown that when human cancer cell
lines are subjected to nutrient stress, such as glutamine depletion,
they preferentially secrete a subtype of exosomes, called Rab11a-
exosomes, from endosomes marked by the small GTPase Rab11a,
one of two Rab11 isoforms44. Secondary cells (SCs) of the Dro-
sophilamale accessory gland (AG) form exosomes as intraluminal
vesicles (ILVs) in highly enlarged Rab11-positive compartments.
These are then secreted into the lumen of the AG, a storage site
for seminal fluid45. These Rab11-exosomes can be selectively
marked by fluorescent transmembrane markers, such as a GFP-
tagged form of the FGF receptor, Breathless (Btl-GFP) or the
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Fig. 2 GAPDH binds to EV surface via G58 domain. aWestern blot showing binding of G58 peptide to HEK293T (designated as 293T) and MSC EVs. The
second domain of TARBP protein was attached to G58 peptide for detection by anti-TARBP2 antibody. The experiment was independently repeated two
times. b NTA profile showing the size distribution of HEK293T EVs after binding to the G58T protein. Inset is the scatter plot representing size (mean) of
EVs. Each dot is a mean of three reading frames taken at different timepoints. Data are shown as mean ± s.d (n= 9 independent biological experiment)
Statistical differences were determined by unpaired two-sided Student’s t-test, (ns= non-significant). c Agarose-gel-shift assay of EVs after incubation
with either G58T (G58+ dsRBD) protein or dsRBD of TARBP2 protein. siRNA alone was used as negative control to determine interaction of EVs with
siRNA. A gradual decrease in the intensity of siRNA reflects entrapment of siRNA near the wells due to interaction with G58T EVs. Lack of siRNA binding
to dsRBD treated EVs confirms G58 peptide mediated binding of protein to EV surface. The experiment was independently repeated three times. d–f High-
resolution single EV analysis by Imaging Flow Cytometry (IFC) to determine localization of GAPDH and G58 peptide on EVs. d Represents method
validation by using either non-labelled HEK293F derived EVs or neon GFP labelled HEK293:CD63-neon GFP derived EVs as biological reference material.
e Detection of GAPDH on HEK293F, HEK293F/CD63-GFP and MSCs EVs, using alexa fluor 647 labelled anti-GAPDH antibody. f G58 peptide binding on
EVs expressing GAPDH on their surface. EVs were incubated with alexa fluor 488 (af488) labelled G58 peptide and af647 anti-GAPDH antibody.
Experiment (d–f) were independently repeated three times. FACS sequential gating/sorting strategies is provided as Supplementary Fig. 9. g Distribution
of secreted GAPDH-GFP protein in the cell-culture media. Media from HEK293T cells expressing GAPDH-GFP protein were processed to isolate EVs from
proteins by gel-filtration chromatography. Both EVs and protein fractions contained GAPDH-GFP protein, indicating vesicular and non-vesicular modes of
GAPDH secretion. Data are shown as mean ± s.d (n= 3 independent biological experiments). Source data are provided as a Source Data file.
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human exosome marker CD63. Interestingly, they form in clus-
ters that surround a large dense-core granule (DCG) of aggre-
gated protein and extend out to the limiting membrane of the
Rab11 compartments (Fig. 3a, b). In Drosophila, there are two
GAPDH isoforms, GAPDH1 and GAPDH2, which are both
closely related in sequence to human GAPDH and may have
partially redundant functions46. Since Drosophila GAPDH has
similar EV-binding properties to human GAPDH (Supplemen-
tary Fig. 4a, b), we tested whether GAPDH might play a role in
ILV clustering.
Overexpression of human GAPDH specifically in adult SCs
produced larger clusters of Btl-GFP-positive ILVs (Fig. 3b), and
increased clustering of Btl-GFP puncta, representing secreted
exosomes, in the AG lumen (Fig. 3c). The ILV clustering
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phenotype was less obvious when SCs were labelled with the
CD63-GFP marker, but CD63-GFP puncta were clearly clustered
in the AG lumen (Supplementary Fig. 4d). Although the number
of ILV-containing compartments was affected by overexpression
of human GAPDH (Supplementary Fig. 43 and 4f), the
proportion of these compartments that contained ILVs was not
significantly altered (Fig. 3d, Supplementary Fig. 4g). We were
unable to detect endogenous GAPDH in SCs. However, an
antibody recognizing human GAPDH identified this molecule in
hGAPDH-overexpressing SCs, in association with membranous
structures inside late endosomal and lysosomal SC compart-
ments, suggesting that it traffics into the endolysosomal system in
SCs, as it does in human cells (Supplementary Fig. 4i).
To test the role of GAPDH in normal exosome biogenesis, we
knocked down the two Drosophila GAPDH genes in SCs. There
was no significant effect of GAPDH1 knockdown on ILV DCG
biogenesis in these cells, when using either the Btl-GFP or CD63-
GFP markers, although exosome secretion was reduced (Fig. 3b,
c, f; Supplementary Fig. 4g and 4h). However, GAPDH2
knockdown led to a severe disruption of DCG formation in SC
compartments. There was no central dense core, but multiple
small dense-cores formed near the limiting membrane (Fig. 3b,
e). Btl-GFP-labelled ILVs were only located in close proximity to
the limiting membrane and around the small DCGs (Fig. 3b, d);
they did not cluster in non-DCG-associated chains, as seen in
normal cells, demonstrating that this process is GAPDH2-
dependent. A similar phenotype was observed with CD63-GFP-
marked ILVs, where the proportion of compartments making
ILVs was also significantly decreased (Supplementary Fig. 3b and
3e). In addition, GAPDH2 knockdown significantly reduced
exosome secretion from these compartments into the AG lumen
(Fig. 3f, Supplementary Fig. 4h).
To check that the identity of DCG compartments had not been
altered by this manipulation, we knocked down GAPDH2 in SCs
expressing YFP-Rab11 from the endogenous Rab11 locus.
Compartments containing defective DCGs were still labelled
with YFP-Rab11 (Supplementary Fig. 5). However, the propor-
tion of these compartments making YFP-Rab11-positive ILVs
was significantly decreased and those ILVs formed were closely
associated with small DCGs or the limiting membrane of each
compartment, confirming that GAPDH2 knockdown specifically
affects ILV clustering and biogenesis. Notably, ILV and DCG
phenotypes were observed with two GAPDH2–RNAi targeting
different sequences, using all three exosome markers, confirming
that the phenotypes did not result from an off-target effect
(Supplementary Figs. 4g and 5). Importantly, the GAPDH2
knockdown phenotype was not recapitulated by knocking down
other glycolytic enzymes, namely Phosphoglucomutase 2 (Pgm2a),
Phosphoglucose isomerase (Pgi) and Phosphofructokinase (Pfk),
suggesting that the observed effects on exosome biogenesis are
not a consequence of general metabolic changes, but rather due to
specific reduction in GAPDH2 expression (Supplementary Fig. 6).
Overall, our data indicate that the formation and clustering of
ILVs and DCG biogenesis in Rab11 compartments of SCs are
regulated by GAPDH2 and appear to be functionally linked
processes, a result supported by a recent analysis of ESCRT
function in SCs47. These findings suggest that the EV clustering
phenotype observed upon human GAPDH overexpression in SCs
and following loading of fly or human GAPDH on human EVs
reflects a normal physiological process in some cell types.
Therapeutic application of free GAPDH binding sites on EVs
in drug delivery. Given the physiological role of GAPDH in
exosome biogenesis and its binding to CD63-positive human EVs,
we reasoned that the binding of the GAPDH G58 peptide to the
outer surface of EVs could be utilized as a specific, but generic,
tool to attach therapeutic moieties to the surface of EVs. As a
proof-of-principle study, we found that the G58T fusion bound
siRNA with high efficiency, as evidenced by gel-shift assay and
spectrofluorimetric analysis (~500–700 siRNA molecules per EV;
Supplementary Fig. 7a and 7b). Moreover, bound siRNA was
protected from degradation by RNase A (Supplementary Fig. 7c)
Confocal microscopy of N2a cells treated with Alexa fluor-633-
labelled G58T EVs loaded with Cy3-labelled siRNA revealed
efficient uptake of complexes by the cells (Fig. 4a). Gene silencing
assays using predesigned Gapdh-targeting siRNA, however,
revealed low levels of gene silencing (~15%) in N2a cells treated
with G58T EV siRNA. Co-localization studies using lysotracker
dye suggested entrapment of the delivered siRNA in late-
endosomes (Supplementary Fig. 7d and 7e). To overcome
endosomal entrapment, we investigated the fusion of different
endosomolytic peptides including TAT, HA2 and the arginine-
Fig. 3 GAPDH regulates exosome biogenesis and clustering in Drosophila secondary cells. a Schematics show male fruit fly and its accessory gland (AG)
containing main cells and secondary cells (SCs), which are only found at the distal tip of the gland. Exosomes can be visualized at the AG lumen as
fluorescent puncta. A schematic of a secondary cell expressing a GFP-tagged form of Breathless (Btl-GFP; green) is also shown. The Rab11 compartments,
which contain intraluminal vesicles (ILVs; green) and dense-core granules (DCGs; dark grey), and the late-endosomes and lysosomes (magenta) are
marked. b Basal wide-field fluorescence and differential interference contrast (‘Merge’) views of living secondary cells (SCs) expressing GFP-tagged form
of Breathless (Btl-GFP; green) with no other transgene (control); or also expressing the open reading frame of the human GAPDH protein (hGAPDH), an
RNAi construct targeting Drosophila GAPDH1 (gapdh1–RNAi #1), or an RNAi construct targeting Drosophila GAPDH2 (gapdh2–RNAi #1). SC outline
approximated by dashed white circles, and acidic compartments are marked by LysoTracker Red (magenta). Btl-GFP-positive intraluminal vesicles (ILVs;
green in ‘Merge’; grey in ‘Zoom’) are apparent inside compartments, surrounding dense-core granules (DCGs; asterisk in ‘Zoom’) and connecting DCGs to
the limiting membrane of the compartment (yellow arrowheads, except in GAPDH2 knockdown, where ILVs only surround peripheral small DCGs). DCG
compartment outline is approximated by white circles. c Confocal transverse images of fixed accessory gland (AG) lumens from the same genotypes,
containing Btl-GFP fluorescent puncta (yellow arrows). d Bar chart showing percentage of DCG compartments per cell containing clustered Btl-GFP-
positive ILVs that are in contact with DCGs (hGAPDH, p= 0.5382; gapdh1–RNAi #1, p > 0.9999; gapdh2–RNAi #1, p < 0.0001; Kruskal–Wallis and Dunn
correction). e Bar chart showing the percentage of DCG compartments per cell containing single spherical DCG (hGAPDH, p > 0.9999; gapdh1–RNAi #1,
p= 0.0816; gapdh2–RNAi #1, p < 0.0001; Kruskal–Wallis and Dunn correction). f Bar chart showing number of Btl-GFP fluorescent puncta in the lumen of
AGs for the different genotypes (hGAPDH, p= 0.0067; gapdh1–RNAi #1, p= 0.0238; gapdh2–RNAi #1, p= 0.0298; Kruskal–Wallis and Dunn correction).
All data are from six-day-old male flies shifted to 29 °C at eclosion to induce expression of transgenes. Genotypes are: w; P[w+, tub-GAL80ts]+; dsx-GAL4,
P[w+, UAS-btl-GFP]/+ with no expression of other transgenes (control) (n= 11 glands/n= 31 cells) (n= 19 AG lumens for ILV secretion), or with UAS-
hGAPDH (n= 10 glands/n= 33 cells)(n= 13 AG lumens), UAS-gapdh1-RNAi (n= 10 glands/n= 32 cells)(n= 11 AG lumens) or UAS-gapdh2-RNAi
overexpression (n= 10 glands/n= 33 cells)(n= 11 AG lumens). Scale bars in (b) (5 µm), in ‘Zoom’ (1 µm), and in c (20 µm). ***p < 0.001, **p < 0.01,
*p < 0.05 and ns non-significant relative to control, Kruskal–Wallis followed by Dunn’s multiple comparison test. Data shown in (d–f) as mean ± SEM (n= 3
independent biological experiments). All experiments shown were independently repeated three times. Source data are provided as a Source Data file.
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rich peptide of flock house nodovirus (FHV) to the G58T protein.
These peptides have previously been successfully used to enhance
the release of drugs from late-endosomes48,49. Attachment of
either two TAT peptides or the FHV peptide to the G58T protein
(designated as G58T(tat)2 and G58TF respectively) resulted in
significantly improved activity with ~35 and 60% silencing of
endogenous genes (GAPDH and HTT) in the cells, respectively
(Fig. 4b; Supplementary Fig. 7f). HA2 chimeric proteins could not
be expressed due to toxicity of the peptide in the E. coli producer
cells. Further treatment of cells with chloroquine, an endoso-
molytic molecule50, enhanced gene silencing efficiency to around
80%, consistent with the release of entrapped siRNA from late-
endosomes (Fig. 4c; Supplementary Fig. 7g and 7h). Taken
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of siRNA into cells by G58T-functionalized EVs, resulting in
potent gene silencing when combined with fusion of endoso-
molytic peptides to G58T protein.
Silencing of Htt gene in the brain of Q140 mice after systemic
administration of G58TF EVs/siRNA. To further assess the
in vivo therapeutic potential of G58-engineered EVs, we inves-
tigated targeted delivery of siRNA into the mouse brain by co-
expressing the RVG peptide on the EV surface. This peptide,
which binds specifically to acetylcholine receptors, has been
extensively used to deliver drugs into the brain51. Previous studies
from our laboratory have shown that RVG increased brain
accumulation of EVs without inducing toxicities in mice52,53. To
determine whether the binding of G58TF (G58T with FHV
domain) protein to the EV surface alters the biodistribution of
RVG-EVs, we systemically injected C57BL/6 mice with RVG-
EVs. Four hours after administration, ~1% of injected EVs were
found in the brain, which is ~4.0 × 1011 EVs for a 20 g of mice.
Similar results have been observed previously while studying
biodistribution of EVs in different tissues of the mice53. Binding
of either G58TF or G58TF/siRNA to RVG-EVs did not change
their biodistribution (Fig. 4d), although, as anticipated, the
majority of EVs were distributed to peripheral tissues, indicating
rapid clearance of EVs from the blood (Supplementary Fig. 8).
To assess the silencing efficiency and therapeutic potential of
G58TF/siRNA-RVG-EVs in the brain, we targeted silencing of
the huntingtin gene (Htt) in the Huntington’s disease (HD)
mouse model Q14054. HD is a neurodegenerative disease caused
by mutation in the huntingtin gene that results in polyglutamine
(poly Q) expansion in the protein, causing death of neurons55.
The monogenic and dominant nature of the disease, and
availability of HD mouse models provides a unique opportunity
to develop and assess therapeutic potential of non-coding RNA in
silencing expression of the mutant Htt gene54. In this study, using
a mixture of siRNA targeting different regions of the Htt exon of
Q140 mice, we systemically administered a total of four doses,
once per week. Analysis of brain tissues revealed almost 40%
silencing of the Htt gene in mouse brain cortex and a highly
significant decrease of p62 inclusion bodies in the cortical
neurons of the treated animals, an important phenotypic HD
marker of disease progression (Fig. 4e, f). p62 is an important
regulatory protein of selective autophagy, and a reduction in p62
aggregates in HD mouse models has previously been shown to
restore HD-associated phenotypes56. However, for reasons that
we currently do not understand, low levels of Htt silencing was
observed in other parts of the brain, which is deserving of further
investigation. Moreover, the slow progression of disease pheno-
types in Q140 mice makes it difficult to determine morphological
and phenotypic changes of HD symptoms in treated mice. Taken
together, our study demonstrated a promising application of G58-
coupled EVs in delivery of siRNA to brain with the potential for
pre-clinical and clinical development.
Discussion
EVs have considerable potential as bio-delivery vehicles, but our
limited understanding of EV biogenesis and loading remains one
of the obstacles in developing these natural signaling mediators as
a therapeutic tool. Here, we demonstrate that endogenous
GAPDH resides on the outer surface of eukaryotic EVs from
multiple cell sources and binds to these vesicles via its
phosphatidylserine-interacting domain. One function of this
interaction is to promote clustering of exosomes, which appears
to play an important role in Rab11-exosome biogenesis and
organizing the large secretory compartments produced by Dro-
sophila secondary cells. We find there are a substantial number of
free GAPDH binding sites on the outer surface of human EVs,
which can be harnessed for loading therapeutic siRNA onto EVs.
Using this approach, we silenced the huntingtin gene in the brain
of a Huntington’s disease mouse model after intravenous
administration.
GAPDH is a multidimensional protein that is intimately
involved in diverse physiological functions and human patholo-
gies. The mechanisms by which these multiple functions are
coordinately regulated remain largely elusive. Unlike other pro-
teins, GAPDH is encoded by a single mRNA species in human
cells. It is, therefore, believed that the multifunctional nature of
the protein is generated by interaction with different cellular
components and acquisition of distinct activities via post-
Fig. 4 G58 peptide promotes EV-mediated siRNA delivery to the brain. a Confocal microscopy image of Neuro-2a cells after 4 h of incubation with
siRNA-loaded G58T EVs. Nuclei of cells were stained with Hoechst 3342. EV surface proteins were labeled with Alexa fluor-633 (red) and siRNA was
labeled with Cy3 dye (green). Inset is the magnified image (scale bar: 2 µm) of the marked region showing co-localization of EVs with siRNA (yellow
spots). Scale bar:10 µm. The experiment was independently repeated four times. b Silencing of GAPDH gene in N2a cells by EVs engineered with G58T,
G58T(tat)2 and G58TF proteins, respectively. Thirty nanomolar of GAPDH siRNA was loaded on to EVs, which were added to cells. Top histogram
represents GAPDH mRNA level determined after 48 h of treatment, using probe-based RT-qPCR. Data were normalized with 18 S rRNA. Mock: G58TF-
bound EVs alone, Neg. Control: G58TF EVs+ non-targeting siRNA. Results shown as mean ± s.d (n= 3 independent biological experiment). Statistical
differences were determined by one-way ANOVA, using Dunnett’s multiple comparisons test. During the analysis, saline group was used as control to
determined statistical significance. **p= 0.0061, ***p= 0.0001. Bottom western blot shows GAPDH protein level in N2a cells after 72 h of treatment. The
experiment was independently repeated three times. c Western blot showing effect of chloroquine (CQ) on silencing of GAPDH protein by G58T and
G58TF EVs in N2a cells. (Mock: G58TF EVs alone, Neg. Control: G58TF EVs+ non-targeting siRNA, RNAiMax: siRNA with lipofectamine RNAiMAX
reagent. Thirty micromolar chloroquine was added to cells along with the EVs. The experiment was independently repeated two times. d In vivo
fluorescence images of C57BL/6 mouse brains showing biodistribution of RVG-EVs, G58TF-RVG-EVs and G58T/siRNA-RVG-EVs. Images were taken
after 4 h of systemic administration of EVs. Surface proteins of RVG-EVs were labeled with cy5.5-NHS fluorescent dye. Mice injected with saline were used
as a negative control. Histogram at the right side shows quantification of the fluorescent signal from the brains of treated mice. (n= 3 mice). Results shown
as mean ± s.d. Statistical differences were determined by one-way ANOVA, using Dunnett’s multiple comparisons test. **p= 0.0011, ***p= 0.0001.
Animal group treated with saline was used as control to determine the p-value. e In vivo silencing of Htt gene in Q140 HD mouse model after systemic
administration of G58TF EVs. Animals received four injections of EVs over four weeks. Seventy two hours after the last dose, animals were sacrificed and
sections of brain were analyzed for Htt mRNA level, using probe-based RT-qPCR. Data were normalized with 18 S rRNA (n= 6 mice). Results are shown as
mean ± s.d. Statistical differences were determined by one-way ANOVA, using Dunnett’s multiple comparisons test. ns non-significant, **P= 0.0012 when
compared to control group (saline). f Immunohistochemistry of cortical regions from the treated animals. Images show mutant HTT protein level and p62-
labeled inclusion bodies in the neurons of the cortex of Htt siRNA and Neg. siRNA-treated animals (Scale bar indicated 15 µm). g Histogram representing
quantification of p62 inclusion bodies. Results are mean ± s.d, n= 8 slides chosen randomly from each group. Statistical differences were determined using
one-way ANOVA (two tails) and post-hoc adjustment using Dunnett’s test. **P= 0.0031 when compared to saline group. Source data are provided as a
Source Data file.
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translational modification in a range of subcellular locations57.
Structural analysis of GAPDH identified NAD+-binding and
catalytic domains of the protein58. In accordance with the earlier
reports, we demonstrated that the PS-binding domain located
within the NAD+ domain is responsible for association with the
surface of EVs. An enzymatic assay confirmed that GAPDH
bound to the EV surface is catalytically active, which is in contrast
to earlier reports where GAPDH isolated from rabbit brain was
found to induce fusion of synthetic liposomes but lacked glyco-
lytic activity37. Catalytic activity of GAPDH has been reported to
play a vital role in trafficking of vesicles along axonal segments of
the nerve cells by providing constant supply of ATP to molecular
motor proteins, but in this case, the GAPDH is located in the
cytosol59. Whether post-translational modifications (PTM) of the
protein have any role in modulating the binding to EVs remains
to be determined. However, due to the limited capacity of bac-
terial cells to introduce PTM60, it appears that these modifications
are not required for EV binding.
To address which domains and/or amino acid residues are
involved in mediating binding of GAPDH to the EV surface, we
developed several GAPDH mutants. Deletion of the catalytic
domain did not affect binding of GAPDH’s NAD+ domain to
EVs. Interestingly, mutation of two amino acid residues within
the PS-binding domain of GAPDH significantly decreased
binding of mutant GAPDH to EVs without affecting its glycolytic
functions, corroborating earlier observations that neither neither
β-NAD+ nor DL-glyceraldehyde-3-phosphate had a significant
effect on binding of GAPDH to PS lipids of the liposomes, sug-
gesting that PS-binding domain is not related to the NAD+
binding site (also known as Rossman fold) or catalytic domain39.
These results further confirm our in vivo observations about non-
enzymatic role of GAPDH in biogenesis of EVs.
GAPDH is one of the top five most common proteins asso-
ciated with EVs61. Some studies have reported the presence of
GAPDH within the EV lumen, but others have identified it on the
EV’s outer surface33,62. Using a simple protease digestion assay to
distinguish internal and external proteins, we found GAPDH
exclusively on the outer surface of EVs. In one recent study,
GAPDH was identified in non-vesicular aggregates from small
EV preparations and was not pulled-down using immunocapture
with magnetic beads coupled to CD63, employed in this analysis
as a putative exosome marker43. However, we have confirmed
that GAPDH is present on the outer surface of human HEK293F-
and MSC-derived EVs using fluorescently labelled anti-GAPDH
antibodies and high-resolution single EV IFCM, and that it co-
associates with a subset of CD63-positive EVs. Whether other
CD63-positive EVs are loaded with low levels of GAPDH that are
below the detection limit of this method remains unclear.
GAPDH was found to bind the EV surface via PS-binding
domain. The limited proportion of vesicles that bear both
GAPDH and CD63 molecules could be due to several reasons,
including low affinity of the GAPDH antibody used in our
experiments, binding of GAPDH to EVs that lack CD63 markers
and alteration of EV markers due to overexpression of CD63-GFP
on the EV surface.
Recently, it has been demonstrated that cytosolic GAPDH
associates with ILVs in early and late-endosomes of human cells
through the process of endosomal microautophagy, which
involves the ESCRT machinery and HSC70 (Heat shock cognate
71 kDa) protein34. This GAPDH is secreted on exosomes and
through its interaction with transferrin and lactoferrin can act as
a sponge, which permits the uptake of free iron. Given these
findings and our observation that exogenous GAPDH leads to EV
clustering, we investigated the role of GAPDH in exosome bio-
genesis, using our unique Drosophila SC model in which clustered
Rab11-exosome formation has recently been visualized in large
endosomal compartments by fluorescence microscopy44. When
overexpressed, human GAPDH trafficked into endosomal com-
partments of SCs and induced vesicle clustering both inside and
outside of these cells, suggesting that the in vitro EV clustering
activity is replicated in vivo. Furthermore, we found that Droso-
phila GAPDH2 has EV clustering activity in vitro and has
important in vivo functions in SCs, since GAPDH2 knockdown
suppressed normal ILV clustering in Rab11-endosomes, reduced
the proportion of ILV-generating compartments and decreased
Rab11-exosome secretion. Similar effects were not observed with
knockdown of other glycolytic enzymes, suggesting this is not the
result of metabolic changes. Importantly, we have found that
human cancer cell lines also produce Rab11-exosomes, particu-
larly under nutrient stress conditions, so our observations are
unlikely to be Drosophila-specific44. GAPDH2 knockdown also
affected the formation of a single large dense-core granule in
Rab11 compartments, consistent with recent ESCRT knockdown
experiments in SCs47, which suggest that exosome and DCG
biogenesis are inter-dependent. Our current model is that clus-
tered ILVs play a role in stabilizing a large DCG in SCs46, but this
does not exclude the possibility that DCGs also affect ILV for-
mation. The reduction in vesicle clustering caused by GAPDH2
knockdown may also affect continued ILV biogenesis. Suppres-
sion of exosome secretion may be partly associated with the
proposed roles of GAPDH in membrane fusion, which have been
shown to regulate secretion of other DCG compartments63. Both
GAPDH1 and GAPDH2 knockdown, but not knockdown of other
glycolytic enzymes, affects Rab11-exosome secretion in SCs,
suggesting that both of these proteins may work together in this
specific process.
Indeed, clustered ILVs have been observed in other cell types in
mammals and nematodes in the absence of DCGs and in specific
pathological scenarios36,64. One common feature in these studies
is that the MVBs involved may not be classical late-endosomes.
Indeed, exosome clustering can be induced when the endolyso-
somal V-ATPase is inhibited, which may suggest a requirement
for more neutral pH and has been suggested to modulate the
range of exosome signaling65. In our analysis, the presence of two
Drosophila GAPDH isoforms may have been critical in allowing
us to define this enzyme’s specific roles in exosome clustering and
biogenesis. By contrast, we found that the levels of knockdown of
the single GAPDH gene in human cells were too variable and led
to excessive toxicity (data not shown), preventing us from
assessing the importance of this molecule in exosome and EV
production in cultured human cells.
We have shown that the PS-binding domain (G58) can be used
in fusion proteins to load cargos on to the surface of EVs, without
the requirement to engineer cells for endogenous loading. Flow
cytometry confirmed that most EVs that already carry surface
GAPDH have many available sites for additional G58T fusion
protein loading. The presence of RNA on the surface of EVs
potentially exposes them to serum nucleases and immune cells,
which could drastically reduce their therapeutic potential. How-
ever, a previous siRNA binding study using the dsRBD of
TARBP2 protein has shown that this domain protects siRNA
from degradation by nucleases and significantly reduces activa-
tion of the innate immune response to siRNA when compared to
naked siRNA, consistent with our finding that G58TF/siRNA has
functional effects in vivo66.
Uptake and gene silencing studies with G58T EVs revealed
trafficking of these EVs to late-endosomes and lysosomes. The
addition of chloroquine and/or G58TF peptide increased siRNA
efficacy, presumably by favouring release from these compart-
ments. Recently a detailed study has demonstrated that endocy-
tosed EVs in large endosomal compartments traffic towards the
endoplasmic reticulum and finally sort into late-endosomes67.
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However, how intravesicular or extravesicular exosomal cargo is
transferred to the cytosol remains unresolved, although the ability
of siRNAs located on either side of the EV membrane to induce
gene knockdown indicates both routes are possible15,16.
Huntington’s (HD) disease is a progressive neurological dis-
order that is caused due to toxic gain of gene function. Currently,
there are no successful drugs to cure the disease68. Recently,
reducing the expression of mutant HTT gene using siRNA has
emerged as a promising treatment69. In our experiments,
although the majority of the EVs administered were rapidly
cleared from each mouse, a small percentage of EVs (~1%) was
found in the brain and was able to knockdown the Htt gene. The
significant reduction of p62 aggregates achieved in the cortex of
Q140 mice at this moderate level of Htt gene silencing highlights
the therapeutic potential of our approach in the treatment of HD.
The knocked-in CAG repeat expansion in Q140 mice and the
consistent expression of the mutant Htt gene and protein in the
brain were important reasons to initially test the therapeutic
potential of G58TF EVs in these mice. However, slow progression
of disease symptoms (>12 months) in Q140 mice makes it diffi-
cult to rapidly assess the behavioural and phenotypic changes of
disease pathology in this model. Therefore, further studies on the
R6/1or R6/2 models, which demonstrate a much more aggressive
phenotype than Q140 mice70, will be necessary to determine the
clinical significance of Htt gene silencing by G58TF EVs. Fur-
thermore, strategies to elevate levels of these EVs in the blood by
expressing the CD47 receptor, which increases retention of cir-
culating EVs15, and by optimization of the G58TF EV formula-
tion should enhance the percentage of gene silencing in the brain
for these experiments.
In summary, we have demonstrated in vitro and in vivo that
GAPDH induces clustering of EVs, and shown that this activity
plays a physiological role in clustering ILVs in endosomal com-
partments of SCs, which appears to impact on other intraluminal
events, such as DCG biogenesis, in these compartments. More
importantly, by engineering GAPDH chimeric proteins that have
retained the G58 EV-binding domain, but do not induce EV
clustering, we have developed a simple and highly robust method
for therapeutic loading of RNA-based drugs on EVs for targeted
drug delivery both in vitro and in vivo in pre-clinical disease
models. The specific and strong affinity of the G58 peptide for
EVs should permit loading of siRNAs onto crude EV prepara-
tions from different cell sources or even biofluids from patients.
Furthermore, the modular design employed for the delivery of
other types of cargoes, ranging from different types of nucleic
acids including guide RNAs, to proteins and peptides, and for
targeting EVs to other specific cells or tissues, thereby enhancing
the therapeutic potential.
Methods
Isolation, purification and characterization of extracellular vesicles.
Mesenchymal stem cells (MSCs), human embryonic kidney cells (HEK293T),
human ovarian cancer cells (SKOVE-3), B-lymphoma cells (B16-F10) and HeLa
cells were used to isolate EVs. All the cells were purchased from ATCC. Cells were
grown in DMEM GlutaMax medium (ThermoFisher Scientific, UK), containing
10% fetal bovine serum and 1 × penicillin-streptomycin (PS, 100 × contains 5000
U/ml of penicillin and 5000 µg/ml streptomycin; Sigma). MSCs were grown in
RPMI GlutaMax media (ThermoFisher Scientific) with 10% FBS and 1 × PS
(Sigma). Cells were maintained at 37 °C with 5% CO2. For isolation of EVs, cells
were seeded in 150 × 20mm dishes (Star Labs, UK) at 106 cells per dish in
DMEM+ 10% FBS media. Twenty four hours after seeding, the media of the cells
was replaced with Opti-MEM reduced serum media (ThermoFisher Scientific, UK).
Cells were incubated further for 48 h followed by collection of media in 50 ml
falcon tubes (Sigma). To remove dead and floating cells, the media was centrifuged
at 500 × g for 5 min. The supernatant was gently transferred into a fresh tube and
centrifuged at 3000 × g for 20 min at 4 °C to pellet cell fragments and remaining cell
debris. Purified media was concentrated by tangential ultrafiltration (TFF), using
100 kDa Vivaflow 50 R cartridges (Sartorius UK limited). Concentrated media was
centrifuged at 10,000 × g for 30 min to remove aggregates and larger particles. The
volume of media was further reduced to 2 ml, using Amicon ultra-15 centrifugal
filter units of 100 kDa MWCO (Millipore). Finally, the media was passed through a
Sepharose 4 fast flow gel-filtration column (GE Healthcare, 170149001), using the
ÄKTA pure chromatography system (GE Healthcare). Purified EVs eluted from the
column were used for the various biological assays. Typically, 500 ml of cell-culture
media was used at the very beginning of the process and concentrated to 2 ml
before loading to the column.
For animal experiments, large quantities of EVs were isolated using a hollow
fibre bioreactor (FibreCell System, UK). 5 × 108 MSCs or HEK293T cells were
seeded into the extra-capillary space (ECS) of a hollow fibre bioreactor cartridge as
per the guidelines of the manufacturer. The level of glucose in the media was
measured on a daily basis to monitor cell growth. After 1 week of growth,
extracellular material was harvested by gently flushing 25 ml of Opti-MEM media
into the ECS from the left end port to collect extracellular material on right end
port of the cartridge. Withdrawn medium was flushed back and forth between the
syringes, through the ECS, four times to dislodge material collected within the fibre
bundles. The resulting harvest was used for isolation of EVs using the differential
centrifugation, ultrafiltration and size-exclusion chromatography methodology as
described above.
Nanoparticle tracking analysis. To measure size distribution and number of EVs,
nanoparticle tracking analysis (NTA) was performed using the NS500 nano-
particles analyser (NanoSight, Malvern, Worcestershire, UK)71. Dilutions of EVs
ranging from 1:500 to 1:1000 in PBS were used to achieve a particle count of
between 2 × 108 and 2 × 109 ml−1. During the recordings, a camera level of 12–14
was used. Using the script control function, three 30 s videos of each sample were
recorded. After each video, a fresh sample was injected into the stage followed by a
delay of 7 s to reduce turbulence of the flow. NTA2.3 software provided by the
manufacturer was used to analyse and measure size and concentration of the EVs.
All NTA measurements were carried out in triplicate.
EV protease digestion assay. HEK293T and HeLa cells were seeded at a density
of 8 × 106 cells in 15 cm cell-culture dishes. After 24 h, cells were co-transfected
with CD81-GFP and DC-LAMP-lactoferrin encoding plasmids and EVs were
isolated 48 h later. Purified EVs were concentrated in Amicon ultra 2 ml centrifugal
filters (Merck, UK) at 4 °C in table-top centrifuge at 3200 × g. Concentrated EVs
were analysed by NTA to determine number of EVs. 1 × 1012 EVs in 30 µl of PBS
buffer were added to PCR tubes. The tubes were divided into three groups as:
Group I: Normal EVs. In this group neither proteases nor denaturants
were added.
Group II: Protease treated EVs. Here, 0.2 µg/µl of pronase (mixture of proteases,
Sigma UK) was added to EVs.
Group III: Denatured EVs treated with proteases. In this group, EVs were
denatured by adding 0.1% triton X-100 followed by heating EVs at 100 °C for
5 min. After EVs were cooled down to room temperature, 0.2 µg/µl of pronase
was added.
Samples treated with Pronase were incubated at 37 °C at different timepoints,
varying from 5 to 60 min. After the incubation, proteases were inactivated by
adding a protease inhibitor (final concentration 10× from 100× stock, Cambridge
Bioscience UK). The samples were further incubated at room temperature for
5 min to allow inactivation of proteases followed by addition of reducing lithium
dodecyl sulfate sample loading buffer (0.5× final concentration, ThermoFisher
Scientific). The samples were immediately transferred into PCR machine
maintained at 70 °C for 10 min. Treated and non-treated EV samples were loaded
into SDS-PAGE (Bolt 4–12%, Bis-Tris gels, ThermoFisher Scientific UK) for
western blotting. For B16-F10, SKOV-3 and MSCs cells, alix protein was used as a
positive control for proteins residing in the lumen of the vesicles.
Electron microscopy. For electron microscopy (EM) analysis of EVs, samples were
prepared as per the protocol described previously72. Briefly, 20 µl drops of purified
EVs were added to parafilm and formvar-carbon-coated EM grids (Agar Scientific,
Stansted, UK), which were floated on the top of EV droplets for 10 min with the
coated side of the grid facing the drop. After the incubation, the grids were carefully
transferred to PBS droplets for washing. Finally, the grids were placed briefly on
water droplets to remove excess salt. For contrasting, grids were initially transferred
to a 50 µl drop of uranyl oxalate solution, pH 7, for 5 min, followed by embedding
in 2% uranyl acetate for 5 min. Next, the grids were carefully removed and excess of
fluid was removed by gently pushing the grid sideways on Whatman no. 1 filter
paper. The grids were air dried and visualized under a JEOL 1010 transmission
electron microscope at 120 kV on an EFI Tecnai 12 TEM (JEOL, Peabody,
MA, USA).
Western blot. For western blotting, EV lysates corresponding to 5–10 µg of total
protein were separated on 4–12% Bis-Tris plus gels (Invitrogen, ThermoFisher
Scientific). Prior to loading, EV proteins were denatured by adding NuPAGE LDS
Sample loading dye and reducing agent (ThermoFisher Scientific) to the EVs and
heated at 70 °C for 10 min. Samples loaded on the gel were run at 150 V for 1 h in
ice-cold NuPAGE MES running buffer. Proteins resolved on the gel were trans-
ferred onto 0.45 µm Immobilon-P, PVDF Membrane (Millipore), using a mini
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transfer blot cell (Bio-Rad). Membranes were blocked with SuperBlock T20 (TBS)
Blocking Buffer (ThermoFisher Scientific) for 1 h at room temperature with gentle
shaking. After blocking, primary antibodies diluted in the blocking buffer were
added to the membrane and incubated overnight at 4 °C on a shaker. Details of the
antibodies used for western blotting of EVs are given in Table S1. After the
incubation, the membranes were washed three times for 5 min each, using 1× tris-
buffered saline, pH 7.6 (TBST, 20 mm Tris base, 150 mM of NaCl and 0.1%
Tween). After the final wash, membranes were incubated with horseradish per-
oxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature with
gentle shaking. Post-incubation, membranes were washed three times for 5 min
each with 1× TBST buffer and developed for by chemiluminescence detection (GE
healthcare, RPN2106). The Odyssey FC imaging system (LI-COR) was used to
visualize the bands on the membrane. Image studio software provided with the
system was used to analyse the data.
For western blotting of proteins from cells, radioimmunoprecipitation assay
(RIPA) buffer (ThermoFisher Scientific) containing 1× protease inhibitor (Halt
protease inhibitor, ThermoFisher Scientific) was added to cells and incubated on
ice for 10 min. Lysates of the cells were passed through 26 G needle syringes several
times and centrifuged at 12,000 × g for 20 min to remove genomic DNA aggregates
and insoluble lipids. Cell supernatants corresponding to 5–10 µg of the total
proteins were used for the western blotting.
Purification of GAPDH from bacterial cells. The cDNA sequence of human
GAPDH (OriGene, UK) was inserted into the pET-28b(+) vector (Novagen). Six
residues of histidine were inserted at the N-terminus for purification by Ni-NTA
chromatography and a FLAG-tag inserted at the C-terminus. The vector was
transformed into BL21(DE3) competent E. coli cells (New
England Biolabs, UK) for expression. Sequences of GAPDH gene and primers
used for cloning are given in Supplementary Table 6. 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG, Sigma) was used to induce expression of the gene in
cells cultured at 37 °C. GAPDH protein was purified by Ni-NTA chromatography
(Qiagen) under native conditions, using standard protocols recommended by the
manufacturer. Ice-cold sodium-phosphate buffer, pH 8.0 (50 mM Na2HPO4/
NaH2PO4, 10 mM Tris-Cl, 300 mM NaCl, 5 mM imidazole) was used during
resuspension and lysis of the BL21(DE3) cells. Purified GAPDH protein was eluted
with 250 mM imidazole in sodium-phosphate buffer, pH 6.0. Protein samples were
dialyzed and passed through a Sephacryl s-200 HR column (GE Health Care) for
further purification. The protein was analysed by SDS-PAGE, and the size of the
protein was confirmed by mass spectrometry, using matrix-assisted laser
desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS).
G58T, G58T(TAT)2 and G58TF chimeric protein. The DNA sequence of
GAPDH gene, which encodes the PS-binding domain (designated as G58), was
fused with the second domain of the human TAR RNA-binding protein (TARBP2,
domain sequence was from UniProtKB; Sequence ID: Q15633). The DNA
sequence corresponding to 58–100 amino acid of GAPDH protein (PS-binding
domain lies between 70–90 amino acids) were selected during fusion with
TARBP2 second domain and recombinant DNA was synthesized commercially
(Integrated DNA technology, Belgium). Additional amino acid sequence of G58
peptide (amino acid sequence from 58 to 69) were chosen for stability of G58
domain while fusing with other domains of the chimeric protein the chimeric
protein. The DNA sequence of TAT and arginine-rich peptide of flock house virus
alpha capsid protein was custom synthesized (Integrated DNA Technology) and
fused to the TARBP2 second domain by PCR cloning. The sequence of G58 peptide
and arrangement of domains in different G58 chimeric proteins is described in
Table S2 and Table S7. The DNA sequences of these chimeric proteins were cloned
into the pET-28b(+) vector. G58T was expressed in BL2(DE3) cells, using similar
conditions to those mentioned above. G58T(TAT)2 and G58TF were expressed in
BL2(DE3) Rosetta (Novagen, Merk, USA). The cells were grown normally at 37 °C
until OD600 reached between 0.5 and 0.6. At this point, 0.2 mM IPTG was added to
the culture, and bacteria were grown at 21 °C for 10–12 h. All versions of G58
chimeric proteins were purified by Ni-NTA chromatography under denaturing
conditions, using 6M urea. Purified proteins were analysed by SDS-PAGE and
MALDI-TOF-MS, as described above. Proteins were refolded by the dilution
method. Briefly, proteins bound to Ni-NTA resin were eluted by 250 mM imida-
zole in sodium-phosphate buffer, containing 2 M urea. Eluted proteins were further
diluted with an equal volume of ice-cold PBS containing 5% glycerol and 0.1 mM
DTT. After 5 min of incubation, the protein was added dropwise to PBS (with
constant stirring) to reduce the urea concentration to 0.5 M. After the dilution,
aggregated proteins were removed by centrifugation at 30,000 × g for 20 min
(Beckman Coulter, USA). Protein was concentrated using centrifugal spin filters
(Millipore) and passed through a PD10 column (GE Healthcare, USA) to remove
final traces of urea.
Generation of GAPDH mutants and their interaction with EVs. Using the
human GAPDH cDNA sequence as a template different types of GAPDH mutant
were developed. For the G150T clone, the NAD+ binding domain of GAPDH was
amplified and fused with the second domain of the TARBP2 protein. The DNA
sequence was inserted into pET-28b(+) for expression in BL21(DE3) E.coli cells as
described above. The protein was purified under denatured conditions using a Ni-
NTA matrix followed by refolding of the protein by gradual dilution of urea
concentration. Purified protein was isolated by gel-filtration column chromato-
graphy. To insert specific single amino acid mutant in wtGAPDH, two codons
specifying Arginine 80 and Lysine 84 were replaced with alanine codons. The
whole gene was synthesized as gBlock (integrated DNA technologies, Belgium) and
inserted into pET-28b vector, using standard restriction digestion and ligation
protocols. After confirming the sequence, mtGAPDH was expressed and purified
from BL21(DE3) E. coli cells using Ni-NTA matrix under native conditions. Both
an enzymatic assay and SDS-PAGE were used to characterize the protein.
For incubation of mtGAPDH with EVs, HEK293T EVs isolated either from a
Bioreactor or by culturing HEK293T cells in optiMEM media were purified using
TFF and gel-exclusion chromatography. 1.4 × 1011 EVs in 700 ul of PBS buffer were
incubated with either wtGAPDH or mtGAPDH for 2 h at 4 °C. Excess of unbound
protein was removed by size-exclusion chromatography. After elution, EVs were
counted by Nanoparticle tracking analysis (NTA) using Nanosight NS500
(Malvern, UK). 3.0 × 108 particles in 10 µl of PBS were taken from each sample for
GAPDH enzymatic kinetic assay (KDalert GAPDH assay, ThermoFisher
Scientific). For immunoblotting, 7.5 × 109 EV particles were heated at 70 °C for
10 min after adding reducing SDS loading dye. Samples were loaded into precast
4–12% Bis-Tris gels (Invitrogen, ThermoFisher Scientific). Proteins resolved on
SDS-PAGE were transferred to a PVD membrane that was incubated with
monoclonal antibodies against the desired proteins. The membrane was developed
with chemiluminescence (GE Health Care, US). Images and quantification of the
gels were carried out with Odyssey FC imaging system (LI-COR).
Binding of GAPDH and G58T chimeric proteins to extracellular vesicles. For
exogenous binding of GAPDH to EVs, purified EVs ranging from 7.5 × 1011 par-
ticles/ml to 1 × 1012 particles/ml were used for incubation with GAPDH and G58
chimeric proteins. Proteins (5–20 nmol as required) were added to 1 pmol of EVs
and incubated for 2 h at 4 °C on a rotor top. Unbound proteins were removed by
gel filtration. Proteins were also added directly to concentrated cell-culture med-
ium, containing fetal calf bovine serum for binding followed by gel filtration to
remove the unbound proteins from the EVs. Binding of GAPDH proteins to the
EV surface was monitored by absorbance at 280 nm (Akta pure, GE Healthcare),
western blot, GAPDH activity assay and gel-shift assay.
GAPDH activity assay. A fluorescence-based KDalert GAPDH assay (Invitrogen,
Life Technologies) was used to measure enzymatic activity of GAPDH protein of
extracellular vesicles. The assay measures the conversion of NAD+ to NADH in the
presence of phosphate and glyceraldehyde-3-phosphate (G-3-P). Under the
recommended assay conditions, the rate of NADH production is proportional to
the amount of GAPDH enzyme present. A fixed number of EVs were added to the
substrate in a 96-well plate. A fluorescent microplate reader (Clariostar Plus, BMG
Labtech) was used to acquire data using the kinetic mode setting, with λex= 560
nm and λem= 590 nm. Data were analyzed using MARS Data Analysis software
(Clariostar Plus, BMG Labtech).
Gel-shift assay. Binding of G58T, G58T(TAT)2 and G58TF EVs to siRNA was
assessed by gel-shift assay. 20 pmol of siRNA was added to a fixed number of EVs
in PBS buffer and incubated for 10 min at room temperature. After the incubation,
complexes were loaded onto a 2% agarose gel stained with 0.5 µg/ml ethidium
bromide for visualization under a UV-transilluminator. Binding of siRNA to EVs
was determined by analyzing the shift of siRNA on the gel. siRNA bound to EVs
remained trapped near the wells while free siRNA migrated freely in the agarose
gel. Using NTA data and the gel-binding assay, the number of siRNAs bound to
EVs was determined.
RNase A protection assay. For the RNase A protection assay, 0.2 mg/ml of RNase
A (Qiagen) was added to EV-siRNA complexes and incubated for 6 h at 37 °C. The
enzyme was inactivated by adding an equal volume of hot SDS lysis solution (2%
SDS, 16 mM EDTA) and incubated at 100 °C for 5 min. siRNA was isolated using
TRIzol reagent (Invitrogen, Life Technologies) and analysed by agarose-gel
electrophoresis.
High-resolution single EV analysis by imaging flow cytometry. For single EV
analysis experiments by Imaging Flow Cytometry (IFCM), EVs were isolated from
HEK293 Freestyle suspension cells (ThermoFisher) and immortalized human cord
blood-derived mesenchymal stromal cells (MSCs; Inscreenex) through ultrafiltra-
tion and bind-elute size-exclusion chromatography (BE-SEC). In brief, conditioned
medium was pre-cleared by low-speed centrifugation (5 min at 700 × g, then
15 min at 2000 × g) and by filtration through 0.22 µm filters (Corning, cellulose
acetate, low protein binding) before it was concentrated and diafiltrated with two
volumes of PBS by tangential flow filtration (300 kDa MidiKros columns, 370 cm2
surface area, Spectrum Labs). EVs were further purified with BE-SEC columns
(HiScreen Capto Core 700 column, GE Healthcare) and concentrated using
Amicon Ultra-15 10 kDa molecular weight cut-off spin filters (Millipore). Particle
concentrations were assessed by nanoparticle tracking analysis with a NanoSight
NS500 instrument. Samples were diluted in PBS 0.2% human albumin (albunorm,
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Octapharma AB) to a final concentration of 1 × 1012 particles/ml before use. For
control purposes, EVs tagged with mNeonGreen (neon GFP) fused to CD63 were
prepared from HEK293 freestyle cells stably expressing CD63-mNeonGreen73.
GAPDH expression and G58 peptide binding were studied on the single EV level
by high-resolution IFCM (Amnis Cellstream, Luminex; equipped with 405, 488,
561 and 642 nm lasers) based on previously optimized settings and protocols with
an Amnis ImagestreamX MkII instrument. In brief, 25 µl of EVs at a concentration
of 1 × 1012 particles/ml were incubated overnight at 4 °C with 400 pmol Alexa-
Fluor488 labelled G58 peptide and/or with AlexaFluor647-labelled rabbit anti
human GAPDH antibodies (abcam, ab204480, clone EPR16884) or APC-labelled
mouse anti human CD63 antibodies (Miltenyi Biotec, 130–100–182; clone H5C6)
at a final concentration of 8 nM in v-bottom 96 wells (ThermoFisher Scientific).
Samples were diluted 1:10,000 in PBS before acquisition using the plate reader of
the Cellstream instrument with FSC turned off, SSC laser set to 40%, and all other
lasers set to 100% of the maximum power. Small EVs were defined as SSC (low) by
using neon GFP-tagged EVs as biological reference material and regions to
quantify fluorescence-positive populations were set according to unstained samples
and single-stained controls. Samples were acquired for 5 min at a flow rate of
3.66 µl/min (setting: slow) with CellStream software version 1.2.3 and analyzed
with FlowJo Software version 10.5.0 (FlowJo, LLC). Dulbecco’s PBS pH 7.4 (Gibco)
was used as sheath fluid.
Confocal microscopy. To determine uptake of siRNA-loaded EVs into cells, N2a
cells were seeded onto coverslips in 6-well tissue culture plates (Sigma). Surface
proteins of EVs were labelled with Alexa Fluor-633 (Invitrogen, Life Technologies).
siRNACy3 was custom synthesized (Integrated DNA Technologies). After 24 h of
seeding cells, complexes of Alexa Fluor-633-labelled EVs and siRNACy3 (20 pmol)
were added to the cells and incubated for 6 h. After the incubation, cells were
washed with PBS containing 20 U/ml heparin sulphate (Sigma), stained with
Hoechst 33258 (Molecular probes, Life technologies) and fixed with 4% paraf-
ormaldehyde (ThermoFisher scientific, UK). The coverslips were mounted on glass
slides using Ibidi mounting medium (Ibidi, Germany) and visualized using a
fluorescence laser confocal microscope, ×60 oil immersion objective lens (FV 1000,
Olympus). The data were processed using FV100 software.
In vitro gene silencing by G58-modified extracellular vesicles. For silencing of
genes in N2a cells and HeLa cells, G58T, G58T(TAT)2 and G58TF proteins were
incubated with either MSC- or HEK293T-derived EVs. After binding, purified EVs
were analyzed for siRNA binding by gel-shift assay, to determine the amount of
EVs needed to completely bind a given amount of siRNA. Using this ratio, EVs
with bound siRNAs were added to the cells in complete DMEM GlutaMax med-
ium. Details of the siRNA used for gene silencing experiment are given in Table S3.
After 24 h of incubation, medium was changed and cells were further incubated.
For mRNA analysis, cells were harvested after 48 h of treatment, using TRIzol
(Invitrogen, Life Technologies). Two hundred and fifty nanograms of total RNA
was used for reverse transcription PCR, using the PrimeScript reverse transcriptase
kit (Takara, Japan). Probe-based reverse transcriptase-quantitative PCR (RT-
qPCR) was used to assess quantities of GAPDH and Htt mRNA. 18 S rRNA and
Hypoxanthine-guanine phosphoribosyl transferase (HPRT) mRNA was used as
reference genes for normalization. PCR efficiencies were determined using Lin-
RegPCR. Data were analyzed using the Pfaffl method74. Details of RT-qPCR assays
are provided in Table S4. For protein analysis, cells were harvested 72 h post
treatment and western blotting performed as described above.
Animal experiments
Biodistribution of extracellular vesicles. All animal experiments were performed in
compliance with the Animals (Scientific Procedures) Act 1986, revised 2012
(ASPA, UK). Six-week-old female C57BL/6 mice were randomly assigned into four
groups (n= 3). HEK293T cells stably transfected with RVG-LAMP-2B protein
were seeded into 15 × 1.2 cm tissue culture plates for isolation of EVs. Immuno-
blotting of EVs and HEK293T cell lysates was carried out to assess expression of
RVG peptide on surface of EVs. RVG-expressing EVs were labeled with sulpho-
Cy5.5-NHS ester dyes (Abcam, ab235032). Briefly, 2 × 1012 EVs in 1 ml PBS buffer
were incubated with 100 µmol of sulpho-Cy5.5-NHS ester, which was prepared in
DMSO as a 10 mM stock. EVs were incubated at room temperature for 1 h with
gentle shaking. After 1 h of incubation, G58TF protein was added to EVs and
incubated for 2 h at 4 °C. Excess dye and protein was removed by passing the EVs
through a gel-filtration column. After concentrating EVs, doses of EVs were given
to animals as described in Table S5. After 4 h of administration, animals were
sacrificed, organs harvested and Cy5.5 fluorescence visualized using the in vivo
animal imaging system (IVIS, Perkin Elmer). Data were analyzed using the IVIS
software.
Silencing of huntingtin gene Htt gene in Q140 Huntington disease model animals.
Q140 mice were used to assess mutant and wild Htt gene silencing by intravenous
administration of siRNA-loaded EVs. In the Q140 mouse model, exon 1 of mouse
Htt is humanized and contains 140 CAG repeats. The mice have a slow progression
of disease phenotype, which starts to appear at the age of 6 months. One-year-old
Q140 mice were assigned to saline, negative siRNA control, and Htt siRNA
treatment groups (n= 6). Saline group was used as a control to assess levels of Htt
mRNA after administering EVs loaded with either negative siRNA (Negative
group) or a mixture of Htt siRNA (treatment group). RVG-EVs bound to G58TF
protein were used for the Htt silencing experiment. EV doses were calculated based
on 0.5 mg/kg siRNA dosage regimen. The number of EVs needed to bind a given
amount of siRNA were calculated by gel-shift assay. One hundred fifty to two
hundred microlitres of EVs were administered intravenously. A total of four doses
were given to animals at weekly intervals. Seventy two hours after the last dose,
animals were euthanized and the various sections of the brain were analyzed for
HttmRNA and protein expression. For determining the level of HTT protein in the
brain tissues, Agarose-gel electrophoresis for resolving aggregates (AGERA) was
carried out to detect mutant HTT protein aggregates. However, we could not
analyze the immunoblot due to high background. Immunohistochemistry of the
cortex regions of the brain was carried out to determine the level of mutant HTT
protein aggregates and p62 inclusion bodies.
Drosophila stocks and genetics. Flies were reared at 25 °C in vials containing
standard cornmeal agar medium (12.5 g agar, 75 g cornmeal, 93 g glucose, 31.5 g
inactivated yeast, 8.6 g potassium sodium tartrate, 0.7 g calcium, and 2.5 g Nipagen
(dissolved in 12 ml ethanol) per litre. They were transferred onto fresh food every
2 days. No additional dried yeast was added to the vials. Temperature-controlled,
SC-specific expression of UAS-CD63-GFP and UAS-Btl-GFP was achieved by
combining these transgenes with the specific driver, dsx-GAL4 and the tempera-
ture-sensitive, ubiquitously expressed repressor tubulin-GAL80ts. Newly enclosed
virgin adult males were transferred to 29 °C to induce post-developmental SC-
specific expression. For overexpression and knockdown experiments, the same
strategy was employed, but in the presence of a UAS transgene or the YFP-Rab11
gene trap. Six-day-old adult virgin males were used throughout this study to ensure
that age- and mating-dependent effects on SC biology were mitigated44,45.
Preparation of accessory glands for live imaging and exosome secretion analysis.
Adult male flies were anaesthetized using CO2. The abdomens were removed from
anaesthetized flies and submerged in PBS (Gibco). The whole male reproductive
tract was carefully pulled out of the body cavity. The accessory glands were isolated
by separation of the ejaculatory bulb from the external genitalia, fat tissues and gut.
Finally, the testes were removed by scission close to the seminal vesicles, as they
often fold over the accessory glands, obscuring imaging.
The isolated accessory glands were transferred to a 9-spot depression glass plate
(Corning PYREX) containing ice-cold PBS and kept on ice until sufficient numbers
had been obtained. They were then stained with ice-cold 500 nM LysoTracker Red
DND-99 (Invitrogen) (1:1000) in 1 × PBS for 5 min. Finally, the glands were rinsed
in ice-cold PBS before being mounted onto high precision microscope cover
glasses. A custom-built holder secured the cover glasses in place during imaging by
wide-field microscopy. To avoid dehydration and hypoxia, the glands were
carefully maintained in a small drop of PBS, surrounded by 10 S Voltalef (VWR
Chemicals), an oxygen-diffusible hydrocarbon oil, and kept stably in place by the
application of a small cover glass (VWR).
Imaging of Drosophila secondary cells. For wide-field imaging, living SCs were
imaged using a DeltaVision Elite wide-field fluorescence deconvolution microscope
(GE Healthcare Life Sciences) equipped with a ×100, NA 1.4 UPlanSApo oil
objective lens (Olympus), and a Cool SNAP HQ2 CCD camera (Photometrics).
The images acquired were typically z-stacks spanning 8–12 µm depth with a
z-distance of 0.2 µm. Images were subsequently deconvolved using the Resolve 3D-
constrained iterative deconvolution algorithm within the softWoRx 5.5 software
package (GE Healthcare Life Sciences).
Confocal images of accessory glands were acquired by using LSM 880 laser
scanning confocal microscope equipped with a ×63, NA 1.4 Plan APO oil DIC
objective (Carl Zeiss). RI 1.514 objective immersion oil (Carl Zeiss) was employed.
Drosophila exosome secretion assay. Virgin six-day-old males of each genotype
were dissected in 4% paraformaldehyde (Sigma–Aldrich) dissolved in PBS. The
glands were left in 4% paraformaldehyde for 15 min to preserve the luminal
contents before being washed in PBT (PBS containing 0.3% Triton X-100,
Sigma–Aldrich) for 5 min. Glands were rinsed with PBS and then mounted onto
SuperFrost Plus glass slides (VWR), removing excess liquid using a Gilson pipette,
and finally immersed in a drop of Vectashield with DAPI (Vector Laboratories) for
imaging by confocal microscopy.
Exosome secretion was measured by sampling within the central third of each
gland. Identical microscope settings and equipment were used throughout. At each
sampling location, ten different z-planes, spaced by 1 μm and at a distance from
any SCs, were analysed.
The automated analysis of exosome secretion by SCs was performed using
ImageJ2, distributed by Fiji. The ‘Noise>Despeckle’ function was first used to
remove background noise, followed by conversion to a binary image. The number
of fluorescent particles was assessed using the ‘Analyse Particles’ function. The
average number of particles for all stacks was then quantified and compared to
controls.
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Analysis of ILV content in dense-core granule compartments. Living SCs from 6-
day-old males of each genotype were imaged using identical settings by wide-field
microscopy. The total number of DCG compartments that contained clustered
fluorescently labelled puncta was counted in each cell, using a full z-stack of the
epithelium. Three individual SCs were analysed from each of ten to fifteen glands.
Dense-core granule compartment analysis. Dense-core granule compartment
numbers were manually quantified in ImageJ2 by using complete z-stacks of
individual cells acquired with differential interference contrast (DIC) microscopy
on the wide-field microscope. The morphology and position of DCGs were also
analysed, and each compartment was scored for the presence of a single spherical
DCG, an abnormally shaped DCG or multiple small fragmented DCGs. Three
individual SCs per gland from each of ten to fifteen glands were used.
Statistical analysis. All data are representative from at least two to three inde-
pendent experiments. The distribution of residuals was tested for normality using
Q–Q plots and the appropriate statistical test was applied. For quantification of
western blots, Image Studio Lite (Li-Cor) software was used. Adobe Photoshop
CS4 software was used to crop and arrange the western blotting, confocal micro-
scopy and electron microscopy figures. Nonparametric one-way ANOVA, using
Bartlett’s and Brown-Forsythe test, was used to calculate F and P-values. For mouse
experiments, data were plotted and analysed, using multivariant (two-tail)
ANOVA. For SC analysis and exosome biogenesis, the Kruskal–Wallis test was
employed followed by Dunn’s test to compare individual control and experimental
datasets. All data analyses and statistics were conducted using GraphPad Prism
v8.0 (GraphPad Software Inc., La Jolla, CA, USA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data accompanies this manuscript. The imaging data are available from the
author upon request. The remaining data are available within the Article and
Supplementary Information. Source data are provided with this paper.
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